Breaking News

AMRI Wins UK Government Contract

September 30, 2013

Will supply product for Phase I trials

AMRI’s subsidiary, Albany Molecular Research (UK) Ltd., has been awarded a seven-year government contract for the development and manufacture of an active ingredient for clinical trials. The contract was awarded by the Defense Science and Technology Laboratory (Dstl), acting on behalf of the UK's Secretary of State for Defence, the Department of National Defence of Canada and Minister of Defence of the Kingdom of the Netherlands.
AMRI will provide development and scale-up of the investigational drug, and the manufacture and supply for Phase I trials. If the trials are successful, AMRI may also become the commercial manufacturer of the product for distribution to the government partners in the contract.
"We are excited for the opportunity to work on this important project for the UK government," said AMRI's president and chief executive officer, Thomas E. D'Ambra, Ph.D. "Government contracts and related collaborations outside of our typical outsourcing contracts with biotechnology and pharmaceutical companies are part of our strategy to diversify our revenue base while making our high-quality services available to all industries, sectors and organizations that can benefit from our strengths in discovery, development and manufacturing."
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research